Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    

AHA Releases Scientific Statement on CAD with Type 2 Diabetes

Walter Clair, MD, MPH

Last month, the American Heart Association released a new scientific statement underscoring the impact of type 2 diabetes management on coronary artery disease.

"Clinical Management of Stable Coronary Artery Disease in Patients with Type 2 Diabetes Mellitus," published April 13 in the journal Circulation, suggests a more aggressive approach might be required to balance the two chronic conditions. In light of emerging evidence, the statement calls for greater consideration when it comes to selecting medication options and interventional procedures. Walter Clair, MD, MPH, board member and past president of the American Heart Association (AHA) Middle Tennessee, discussed the significance of this new scientific statement.

"Most of our focus as cardiologists has been on decreasing cardiovascular mortality," he pointed out. In order to address the lagging indicator of decreased cardiovascular disease, there has to be focused attention on the leading indicators, which are the risk factors leading to CAD, he noted. "We know hypertension, diabetes and smoking increase the risk of cardiovascular disease ... but the link between diabetes and cardiovascular disease has never been as important to us as the link between hypertension and cardiovascular disease," said Clair, who serves as executive director and chief medical officer for the Vanderbilt Heart & Vascular Institute.

This new statement is meant to focus a spotlight on the risks of type 2 diabetes (T2D), as well. "We've now come to appreciate the fact that diabetes is not just ambient ... a coincidental 'other disease,'" Clair said, adding T2D significantly complicates cardiologists' efforts to decrease coronary artery disease (CAD).

Over the last couple of decades, new classes of drugs beyond insulin have come online to treat diabetes. Clinical studies leading to Food and Drug Administration approval of thiazolidinediones (TZDs) found the drugs quite effective in lowering blood sugars, but meta analyses began to emerge a little more than a decade ago showing increased risk of cardiovascular morbidity and mortality with TZD usage. "That is what initially caught the attention of cardiologists," said Clair.

As a result, the FDA issued guidance in 2008 calling for new T2D therapy developers to conduct large cardiovascular outcomes trials to demonstrate safety. It should be noted, though, new draft guidance just released by the agency in March no longer includes that recommendation.

However, the resulting focus on cardiovascular safety from 2008 has led to a much better understanding of the cardiac profile for both newer drugs and well established therapies. For example, metformin - the most frequently prescribed medication to lower glucose for initial treatment in T2D patients - sometimes leads to weight loss and is at least neutral in terms of cardiovascular effects. The AHA scientific statement noted there are newer classes of drugs where research indicates a bigger win/win in terms of diabetes and heart disease.

"The wonderful, surprising finding in these new drugs is that not only do they not worsen the cardiovascular morbidity profile, they actually make it better," said Clair.

Sodium-glucose co-transporter inhibitors (SGLT2 inhibitors), which are taken orally, were the first to show weight loss, reduced risk of heart failure and less progression of chronic kidney disease. Glucagon-like peptide-1 agonists (GLP-1 receptor agonists), which are injectable medications, both lower blood glucose levels and can also help with weight reduction. While there has been some mixed results in terms of actually reducing cardiovascular diseases, the AHA statement said some "GLP-1 receptor agonists have been shown to reduce the risk of major cardiovascular events caused by cholesterol build-up in the arteries, such as heart attacks and strokes."

The statement also pointed out that although aspirin is often appropriate for people with heart disease, it might not be as effective in people with T2D and CAD. For those with both chronic conditions, using newer antiplatelet medications might be more effective. Similarly, T2D could also influence the type of interventional procedure deemed best to reopen an artery. The AHA statement reads, "Studies have found a greater reduction in the five-year risk of death, heart attack or recurrent angina/chest pain when patients with T2D and CAD undergo coronary artery bypass graft (CABG) surgery to widen a narrowed blood vessel instead of treating the narrowing with angioplasty and stenting."

Clair said having the new AHA statement in hand underscores the need to consider the bigger picture when caring for patients with T2D and CAD and serves as a reminder to cardiologists, endocrinologists and primary care providers to consider all options. He added the 'big picture' includes being good stewards of resources.

"The newer drugs always cost more and might not be covered by insurers," he pointed out. "But if you're looking at the morbidity of patients, they really do better on these newer drugs." Clair added oral SGLT2 inhibitors are about half the cost of the more expensive injectable GLP-1 receptor agonists but said both cost considerably less than the expenditures of money, lower quality of life and lost productivity that are associated with a heart attack.

"If patients are getting good control from standard medications and they don't have known heart disease - fine," said Clair. "But, if they do have cardiovascular disease, the risk/benefit ratio shifts."

As for lifestyle and nutritional changes, Clair said establishing good habits is the baseline for treatment of both T2D and CAD. He added most patients really want to try to address high blood pressure, high cholesterol, diabetes and other issues without medication.

"I used to let them try lifestyle changes (first), but then they come back to see me and weigh six pounds more. Now I've shifted my view," Clair said. "I tell them, 'Let's use the drugs to get your condition under control, then if your lifestyle changes work, we'll look at backing off the medications.'"

Clair added an improved understanding of the pathophysiology of both T2D and CAD has allowed newer diabetes medications to offer more benefits while reducing cardiovascular risks. In this new era, he concluded, "We're moving more aggressively toward prevention."

The scientific statement was developed on behalf of the American Heart Association's Council on Lifestyle and Cardiometabolic Health and Council on Clinical Cardiology. Suzanne V. Arnold, MD, MHA, associate professor of medicine at the University of Missouri Kansas City, served as chair of the writing committee. Access the full statement through the AHA website at in the 'Guidelines and Statements' section under the 'Professionals' tab or through the link posted with this article on our website at


AHA Clinical Management of CAD in Patients with T2D


Related Articles:

Recent Articles

New Study Looks at Cost Impact of OTC Birth Control

A new study explores the impact on unintended pregnancies, consistent use of progestin-only OTC birth control pills at various price points.

Read More

Behavioral Health in a Time of Social Isolation

Last month, the Nashville Health Care Council brought together experts for a virtual panel discussion on behavioral health in the midst of social distancing orders.

Read More

COVID-19 & Mental Health

As the virus takes its toll, providers are finding new ways to reach patients and preparing for the mental health fallout ahead.

Read More

Self-Care on the Front Lines of Coronavirus

Physicians, nurses, respiratory therapists and the full complement of support staff at hospitals and clinics are battling coronavirus on the front lines. When caring for others, it's all too easy to forget to take care of yourself.

Read More

Sharing Best Practices in Behavioral Health

Nashville-based online video service provides evidence-based training to public and providers.

Read More

May is Mental Health Month

May is Mental Health Month with excellent resources from national organizations for both patients and providers.

Read More

Business Insights

Read More

Celebrating 15 Years of Incredible Leaders

Following are the 15 classes of Women to Watch. Some of these trailblazers have happily retired after a career of service. Others have moved to other positions and taken up new challenges since they were first recognized.

Read More

New Study Looks at Cost Impact of OTC Birth Control

A new study explores the impact on unintended pregnancies, consistent use of progestin-only OTC birth control pills at various price points.

Read More

AHA Releases Scientific Statement on CAD with Type 2 Diabetes

A new AHA scientific statement explores more aggressive clinical options for the patient-centered management of individuals with both type 2 diabetes and coronary artery disease.

Read More

Email Print



AHA, American Heart Association, American Heart Association of Middle Tennessee, CABG, CAD, Chronic Disease Management, Coronary Artery Disease, GLP-1 Receptor Agonists, Heart Disease, SGLT2 Inhibitors, T2D, Type 2 Diabetes, Vanderbilt Heart and Vascular Institute, VHVI, Walter Clair
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: